Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade B 39.98 0.20% 0.08
ACAD closed up 0.2 percent on Thursday, October 17, 2019, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Oct 30

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ACAD trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Overbought Stochastic Strength 0.00%
Multiple of Ten Bearish Other 0.20%
Overbought Stochastic Strength 0.20%
Stochastic Reached Overbought Strength -0.45%
Multiple of Ten Bullish Other -0.45%
Overbought Stochastic Strength -0.45%
Multiple of Ten Bearish Other 1.27%

Older signals for ACAD ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Chemistry Health Biopharmaceutical Pharmaceutical Industry Chemical Compounds Medication Alzheimer's Disease Parkinson's Disease Schizophrenia Glaucoma Neurological Disorders Chronic Pain Treatment Of Parkinson's Disease Treatment Of Alzheimer's Disease Treatment Of Glaucoma Allergan
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 44.84
52 Week Low 14.01
Average Volume 2,200,744
200-Day Moving Average 27.3303
50-Day Moving Average 34.8008
20-Day Moving Average 38.9345
10-Day Moving Average 39.625
Average True Range 1.8063
ADX 28.92
+DI 26.4678
-DI 15.7672
Chandelier Exit (Long, 3 ATRs ) 37.9211
Chandelier Exit (Short, 3 ATRs ) 40.7689
Upper Bollinger Band 41.9748
Lower Bollinger Band 35.8942
Percent B (%b) 0.67
BandWidth 15.617511
MACD Line 1.3245
MACD Signal Line 1.5095
MACD Histogram -0.185
Fundamentals Value
Market Cap 4.89 Billion
Num Shares 122 Million
EPS -2.53
Price-to-Earnings (P/E) Ratio -15.80
Price-to-Sales 67.33
Price-to-Book 10.21
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.03
Resistance 3 (R3) 41.08 40.79 40.86
Resistance 2 (R2) 40.79 40.52 40.76 40.80
Resistance 1 (R1) 40.38 40.35 40.24 40.33 40.74
Pivot Point 40.09 40.09 40.01 40.06 40.09
Support 1 (S1) 39.68 39.82 39.54 39.63 39.22
Support 2 (S2) 39.39 39.65 39.36 39.16
Support 3 (S3) 38.98 39.39 39.11
Support 4 (S4) 38.93